中新网8月1日电（赵方园）近日，中国国家药监局（NMPA）正式批准了华熙生物申报的“注射用透明质酸钠复合溶液”上市，该产品适用于纠正颈部皱纹，注册证编号为国械注准20243131359。这是继爱美客旗下“嗨体”产品之后，市场上出现的又一针对颈部皱纹的注射产品。
华熙生物相关负责人确认了这一消息，并表示该产品为Ⅲ类医疗器械，目前尚未推广。据了解，“透明质酸钠复合溶液”是一种包含多种营养成分的注射产品，用于改善皮肤表面的浅层皱纹。在中国，这类产品必须获得械Ⅲ类注册证才能合法使用。
此前，“嗨体”作为国内唯一一款专注于改善颈纹的注射产品，自2016年12月获得Ⅲ类医疗器械注册证以来，一直处于市场领先地位。爱美客财报数据显示，自2020年以来，以“嗨体”为主的溶液类注射产品收入持续增长，占总营收比重在60%以上，成为公司业绩的主要来源。
随着华熙生物产品的获批，市场担心可能会对“嗨体”的销量造成影响。不过，截至发稿时，爱美客董秘办未回应中新健康的相关采访提纲。
值得注意的是，爱美客股价在8月1日收盘时下跌1.49%，收报172.98元/股，总市值较此前巅峰时刻已大幅缩水。市场人士分析，随着竞争的加剧，爱美客可能需要采取措施巩固其在市场上的地位。
未来，随着更多同类产品的推出，市场竞争将更加激烈，消费者也将有更多选择。同时，这也将促进企业不断研发新技术，提高产品性能，以满足市场需求。
英语如下：
News Title: “Hua Xi Biological’s New Product Approved for Neckline Wrinkle Market Competition”
Keywords: Hua Xi Approved, Hitech Competitor, Neckline Wrinkles
News Content:
BEIJING, Aug. 1 (Xinhua) — The National Medical Products Administration (NMPA) has officially approved the application by Hua Xi Biological for its “Injection Hyaluronic Acid Complex Solution,” which is designed to correct neck wrinkles. The product, with a registration certificate number of 20243131359, is now available on the market. This marks the second injection product specifically targeting neck wrinkles, following Hitech’s product from Elem.com.
A spokesperson from Hua Xi Biological confirmed the approval and stated that the product is classified as Class III medical devices, which have not yet been launched for promotion. The “Hyaluronic Acid Complex Solution” is an injection product containing various nutritional components, intended to improve fine lines on the skin’s surface. In China, such products must obtain a Class III medical device registration certificate to be legally used.
Hitech’s product, as the only domestic injection product dedicated to improving neck wrinkles since its Class III medical device registration certificate was obtained in December 2016, has maintained a leading position in the market. According to Elem.com’s financial reports, the revenue from hyaluronic acid injection products, led by Hitech, has been steadily growing since 2020, accounting for more than 60% of the company’s total revenue, making it the main source of earnings.
With the approval of Hua Xi Biological’s product, there are concerns that Hitech’s sales may be affected. However, as of the time of publication, the Elem.com secretariat did not respond to the interview outline from Xinhua Health.
It is noteworthy that Elem.com’s stock price fell by 1.49% on August 1, closing at 172.98 yuan per share, with the total market value significantly reduced from its peak. Market analysts believe that with increased competition, Elem.com may need to take measures to solidify its position in the market.
Looking ahead, as more similar products are introduced to the market, competition is expected to intensify, providing consumers with more options. This will also encourage companies to continuously develop new technologies and improve product performance to meet market demand.
【来源】http://www.chinanews.com/cj/2024/08-01/10261656.shtml
Views: 1